

## PRIOR AUTHORIZATION POLICY

**POLICY:** Weight Loss – Glucagon-Like Peptide-1 Agonists Prior Authorization Policy

- Saxenda® (liraglutide subcutaneous injection – Novo Nordisk)
- Wegovy® (semaglutide subcutaneous injection – Novo Nordisk)
- Zepbound™ (tirzepatide subcutaneous injection – Eli Lilly)

**REVIEW DATE:** 07/12/2023; selected revision 07/26/2023, 09/13/2023, 11/15/2023, 01/31/2024

---

### OVERVIEW

Saxenda, Wegovy, and Zepbound, are glucagon-like peptide-1 (GLP-1) receptor agonists; Zepbound is also a glucose-dependent insulintropic polypeptide (GIP) receptor agonist.<sup>1,2,9</sup> Saxenda and Zepbound are indicated as an adjunct to a reduced-calorie diet and increased physical activity for **chronic weight management** in the following settings:<sup>2,9</sup>

- **Saxenda and Zepbound:** Adults with an initial body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup> (obese), or  $\geq 27$  kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension<sup>2,9</sup>, dyslipidemia<sup>2,9</sup>, type 2 diabetes<sup>2,9</sup>, obstructive sleep apnea<sup>9</sup>, or cardiovascular disease<sup>9</sup>).
- **Saxenda:** Pediatric patients  $\geq 12$  years of age with body weight  $> 60$  kg and an initial BMI corresponding to 30 kg/m<sup>2</sup> for adults (obese) by international cutoffs.<sup>2</sup>

**Wegovy** is indicated in combination with a reduced-calorie diet and increased physical activity:<sup>1</sup>

- To **reduce the risk of major adverse cardiovascular (CV) events** (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.<sup>1,10</sup>
- To **reduce excess body weight and maintain weight reduction long term** in:
  - Adults with overweight in the presence of at least one weight-related comorbid condition.<sup>1,11</sup>
  - Adults and pediatric patients  $\geq 12$  years of age with obesity.<sup>1,12</sup>

### Dosing

In the prescribing information for Saxenda, a recommended dose escalation schedule of 4 weeks is outlined.<sup>2</sup> If a patient does not tolerate an increased dose during dose escalation, consider delaying dose escalation for approximately one additional week. For adults, the recommended maintenance dose of Saxenda is 3 mg once daily (QD); discontinue Saxenda if the patient cannot tolerate the 3 mg dose. Additionally, for adults, the prescribing information states to evaluate the change in body weight 16 weeks after initiating Saxenda and discontinue Saxenda if the patient has not lost at least 4% of baseline body weight, since it is unlikely the patient will achieve and sustain clinically meaningful weight loss with continued treatment. For pediatric patients, the recommended maintenance dose of Saxenda is 3 mg QD. However, pediatric patients who do not tolerate 3 mg QD may have their maintenance dose reduced to 2.4 mg QD. Discontinue Saxenda if the patient cannot tolerate the 2.4 mg dose. Additionally, for pediatric patients, the prescribing information states to evaluate the change in BMI after 12 weeks on the maintenance dose and discontinue Saxenda if the patient has not had a reduction in BMI of at least 1% from baseline, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.

In the prescribing information for Wegovy, a recommended dose escalation schedule of 16 weeks is outlined.<sup>1</sup> If a patient does not tolerate an increased dose during dose escalation, consider delaying dose escalation for 4 weeks. The maintenance dose of Wegovy is 2.4 mg (recommended) or 1.7 mg injected

---

subcutaneously (SC) once weekly; consider treatment response and tolerability when selecting the maintenance dose. The 0.25 mg, 0.5 mg, and 1 mg once weekly doses are initiation and escalation doses and are not approved doses for chronic weight management. If a pediatric patient  $\geq 12$  to  $< 18$  years of age does not tolerate the maintenance dose of 2.4 mg once weekly, the dose can be reduced to 1.7 mg once weekly. Discontinue Wegovy if the patient cannot tolerate the 1.7 mg dose.

In the prescribing information for Zepbound, the recommended starting dose is 2.5 mg injected SC once weekly.<sup>9</sup> The 2.5 mg dose is for treatment initiation and is not intended for chronic weight management. After 4 weeks, the dose can be increased to 5 mg SC once weekly. The dose can then be increased in 2.5 mg increments, after at least 4 weeks on the current dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg SC once weekly. The treatment response and tolerability should be considered when selecting the maintenance dose. If a patient does not tolerate a maintenance dose, consider a lower maintenance dose. The maximum dose is 15 mg SC once weekly. The 5 mg, 10 mg, and 15 mg maintenance doses would be reached after Week 4, Week 12, and Week 20, respectively.

### **Guidelines**

Guidelines from the American Gastroenterological Association on pharmacological interventions for adults with obesity (2022) state that in adults with obesity or overweight with weight-related complications, who have had an inadequate response to lifestyle interventions, it is recommended to add pharmacological agents to lifestyle interventions over continuing lifestyle interventions alone (strong recommendation, moderate quality evidence).<sup>6</sup> Wegovy and Saxenda are listed among the therapeutic options. It is also noted that given the magnitude of net benefit, Wegovy may be prioritized over other approved anti-obesity medications for the long-term treatment of obesity for most patients.

Guidelines from the Endocrine Society regarding pharmacological management of obesity (2015) recommend pharmacotherapy as adjunct to behavioral modification to reduce food intake and increase physical activity for patients with BMI  $\geq 30$  kg/m<sup>2</sup> or  $\geq 27$  kg/m<sup>2</sup> in the presence of at least one comorbidity, such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.<sup>3</sup> If a patient's response to a weight loss medication is deemed effective (weight loss  $\geq 5\%$  of body weight at 3 months) and safe, it is recommended that the medication be continued. In clinical studies of Saxenda and semaglutide, eligible patients were required to have a prior unsuccessful dietary weight loss attempt. The American Diabetes Association also cites weight loss  $\geq 5\%$  of body weight at 3 months as "effective"; when early response is insufficient (typically  $< 5\%$  weight loss after 3 months), other therapies should be evaluated.<sup>8</sup>

Per American Association of Clinical Endocrinologists/American College of Endocrinology obesity guidelines (2016), pharmacotherapy for overweight and obesity should be used only as an adjunct to lifestyle therapy and not alone.<sup>4</sup> The addition of pharmacotherapy produces greater weight loss and weight-loss maintenance compared with lifestyle therapy alone. The concurrent initiation of lifestyle therapy and pharmacotherapy should be considered in patients with weight-related complications that can be ameliorated by weight loss. Pharmacotherapy should be offered to patients with obesity, when potential benefits outweigh the risks, for the chronic treatment of the disease. Short-term treatment (3 to 6 months) using weight-loss medications has not been demonstrated to produce longer-term health benefits and cannot be generally recommended based on scientific evidence.

### *Guidelines in Pediatric Obesity*

Guidelines from the American Academy of Pediatrics on evaluation and treatment of children and adolescents with obesity (2023) note that pediatricians and other primary health care providers should offer adolescents  $\geq 12$  years of age with obesity (BMI  $\geq 95^{\text{th}}$  percentile) weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment.<sup>7</sup>

A 2017 Endocrine Society clinical practice guideline on pediatric obesity recommends that pharmacotherapy in combination with lifestyle modification be considered in obese children or adolescents only after failure of a formal program of intensive lifestyle (dietary, physical activity and behavioral) modification to limit weight gain or to ameliorate comorbidities.<sup>5</sup> The Endocrine Society recommends pharmacotherapy in overweight children and adolescents < 16 years of age only in the context of a clinical trial. Pharmacotherapy should be provided only by clinicians who are experienced in the use of anti-obesity agents and aware of the potential for adverse events. These guidelines recommend limited use of pharmacotherapy because pediatric obesity should be managed preferably as a serious lifestyle condition with important lifelong consequences. The Endocrine Society defines overweight as BMI in at least the 85<sup>th</sup> percentile but less than the 95<sup>th</sup> percentile, and obesity as BMI in at least the 95<sup>th</sup> percentile for age and sex against routine endocrine studies, unless the height velocity is attenuated or inappropriate for the family background or stage of puberty.<sup>5</sup>

### **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Saxenda, Wegovy, and Zepbound. Of note, this policy targets Saxenda, Wegovy, and Zepbound; other glucagon-like peptide-1 agonists which do not carry an FDA-approved indication for weight loss are not targeted in this policy. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

**Automation:** None.

### **RECOMMENDED AUTHORIZATION CRITERIA**

**I.** Coverage of Saxenda is recommended in those who meet the following criteria:

#### **FDA-Approved Indications**

- 1. Weight Loss, Adult.** Approve for the duration noted if the patient meets one of the following (A or B):
  - A) Initial Therapy.** Approve for 4 months if the patient meets the following (i, ii, iii, and iv):
    - i.** Patient is  $\geq 18$  years of age; AND
    - ii.** Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND
    - iii.** Patient meets one of the following (a or b):
      - a)** At baseline patient had a BMI  $\geq 30$  kg/m<sup>2</sup>; OR  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
      - b)** At baseline, patient had a BMI  $\geq 27$  kg/m<sup>2</sup> and at least one of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease; AND  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
  - iv.** The medication will be used concomitantly with behavioral modification and a reduced-calorie diet.

- B) Patient is Continuing Therapy with Saxenda.** Approve for 1 year if the patient meets the following (i, ii, iii, iv, and v):

Note: For a patient who has not completed 4 months of initial therapy, refer to Initial Therapy criteria above.

i. Patient is  $\geq 18$  years of age; AND

ii. Patient meets one of the following (a or b):

a) At baseline, patient had a BMI  $\geq 30$  kg/m<sup>2</sup>; OR

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).

b) At baseline, patient had a BMI  $\geq 27$  kg/m<sup>2</sup> and at least one of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease; AND

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).

iii. Patient has lost  $\geq 4\%$  of baseline body weight; AND

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).

iv. Patient is able to tolerate a Saxenda maintenance dose of 3 mg once daily; AND

v. The medication will be used concomitantly with behavioral modification and a reduced-calorie diet.

- 2. Weight Loss, Pediatric.** Approve for the duration noted if the patient meets one of the following (A or B):

- A) Initial Therapy.** Approve for 4 months if the patient meets the following (i, ii, iii, and iv):

i. Patient is  $\geq 12$  years of age and  $< 18$  years of age; AND

ii. Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND

iii. At baseline, patient had a BMI  $\geq 95^{\text{th}}$  percentile for age and sex; AND

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).

iv. The medication will be used concomitantly with behavioral modification and a reduced-calorie diet.

- B) Patient is Continuing Therapy with Saxenda.** Approve for 1 year if the patient meets the following (i, ii, iii, iv, and v):

Note: For a patient who has not completed 4 months of initial therapy, refer to Initial Therapy criteria above.

i. Patient is  $\geq 12$  years of age and  $< 18$  years of age; AND

ii. At baseline, patient had a BMI  $\geq 95^{\text{th}}$  percentile for age and sex; AND

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).

iii. Patient has had a reduction in BMI of  $\geq 1\%$  from baseline; AND

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).

- iv. Patient is able to tolerate a Saxenda maintenance dose of 2.4 mg once daily or 3 mg once daily; AND
- v. The medication will be used concomitantly with behavioral modification and a reduced-calorie diet.

II. Coverage of Wegovy is recommended in those who meet one of the following criteria:

### FDA-Approved Indications

1. **Weight Loss, Adult.** Approve for the duration noted if the patient meets one of the following (A or B):

A) Initial Therapy. Approve for 7 months if the patient meets the following (i, ii, iii, and iv):

- i. Patient is  $\geq 18$  years of age; AND
- ii. Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND
- iii. Patient meets one of the following (a or b):
  - a) At baseline, patient had a BMI  $\geq 30$  kg/m<sup>2</sup>; OR  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
  - b) At baseline, patient had a BMI  $\geq 27$  kg/m<sup>2</sup> and at least one of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease; AND  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
- iv. The medication will be used concomitantly with behavioral modification and a reduced-calorie diet.

B) Patient is Continuing Therapy with Wegovy. Approve for the duration noted below if the patient meets the following (i, ii, iii, iv, and v):

Note: For a patient who has not completed 7 months of initial therapy, refer to Initial Therapy criteria above.

- i. Patient is  $\geq 18$  years of age; AND
- ii. Patient meets one of the following (a or b):
  - a) At baseline, patient had a BMI  $\geq 30$  kg/m<sup>2</sup>; OR  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
  - b) At baseline, patient had a BMI  $\geq 27$  kg/m<sup>2</sup> and at least one of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease; AND  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
- iii. Patient has lost  $\geq 5\%$  of baseline body weight; AND

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulintropic polypeptide (GIP) receptor agonist (e.g., Zepbound).

- iv. The medication will be used concomitantly with behavioral modification and a reduced-calorie diet; AND
- v. Patient meets one of the following (a or b):
  - a) Patient is able to tolerate a Wegovy maintenance dose of 1.7 mg once weekly or 2.4 mg once weekly: Approve for 1 year; OR
  - b) Approve for up to 5 months if the patient meets both of the following [(1) and (2)]:
 

Note: Approve a sufficient duration for 12 consecutive months of therapy (for example, if the patient has completed 8 months of Wegovy therapy, approve for 4 additional months).

    - (1) Patient has received < 12 consecutive months of Wegovy; AND
    - (2) According to the prescriber, the patient is continuing to titrate the Wegovy dose to a target of 1.7 mg once weekly or 2.4 mg once weekly.

**2. Weight Loss, Pediatric.** Approve for the duration noted if the patient meets one of the following (A or B):

**A) Initial Therapy.** Approve for 7 months if the patient meets the following (i, ii, iii, and iv):

- i. Patient is  $\geq 12$  years of age and  $< 18$  years of age; AND
- ii. Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND
- iii. At baseline, patient had a BMI  $\geq 95^{\text{th}}$  percentile for age and sex; AND
 

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulintropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
- iv. Wegovy will be used concomitantly with behavioral modification and a reduced-calorie diet.

**B) Patient is Continuing Therapy with Wegovy.** Approve for the duration noted below if the patient meets the following (i, ii, iii, iv, and v):

Note: For a patient who has not completed 7 months of initial therapy, refer to Initial Therapy criteria above.

- i. Patient is  $\geq 12$  years of age and  $< 18$  years of age; AND
- ii. At baseline, patient had a BMI  $\geq 95^{\text{th}}$  percentile for age and sex; AND
 

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulintropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
- iii. Patient has had a reduction in BMI of  $\geq 1\%$  from baseline; AND
 

Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulintropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
- iv. The medication will be used concomitantly with behavioral modification and a reduced-calorie diet; AND
- v. Patient meets one of the following (a or b):
  - a) Patient is able to tolerate a Wegovy maintenance dose of 1.7 mg once weekly or 2.4 mg once weekly: Approve for 1 year; OR
  - b) Approve for up to 5 months if the patient meets both of the following [(1) and (2)]:
 

Note: Approve a sufficient duration for 12 consecutive months of therapy (for example, if the patient has completed 8 months of Wegovy therapy, approve for 4 additional months).

    - (1) Patient has received < 12 consecutive months of Wegovy; AND
    - (2) According to the prescriber, the patient is continuing to titrate the Wegovy dose to a target of 1.7 mg once weekly or 2.4 mg once weekly.

**III. Coverage of Zepbound is recommended in those who meet one of the following criteria:**

**FDA-Approved Indications**

**1. Weight Loss, Adult.** Approve for the duration noted if the patient meets one of the following (A or B):

**A) Initial Therapy.** Approve for 8 months if the patient meets the following (i, ii, iii, and iv):

- i.** Patient is  $\geq 18$  years of age; AND
- ii.** Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND
- iii.** Patient meets one of the following (a or b):
  - a)** At baseline, patient had a BMI  $\geq 30$  kg/m<sup>2</sup>; OR  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
  - b)** At baseline, patient had a BMI  $\geq 27$  kg/m<sup>2</sup> and at least one of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease; AND  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
- iv.** The medication will be used concomitantly with behavioral modification and a reduced-calorie diet.

**B) Patient is Continuing Therapy with Zepbound.** Approve for the duration noted below if the patient meets the following (i, ii, iii, iv, and v):

Note: For a patient who has not completed 8 months of initial therapy, refer to Initial Therapy criteria above.

- i.** Patient is  $\geq 18$  years of age; AND
- ii.** Patient meets one of the following (a or b):
  - a)** At baseline, patient had a BMI  $\geq 30$  kg/m<sup>2</sup>; OR  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
  - b)** At baseline, patient had a BMI  $\geq 27$  kg/m<sup>2</sup> and at least one of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, non-alcoholic fatty liver disease, polycystic ovarian syndrome, or coronary artery disease; AND  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
- iii.** Patient has lost  $\geq 5\%$  of baseline body weight; AND  
Note: This refers to baseline prior to any glucagon-like peptide-1 (GLP-1) agonist (e.g., Saxenda, Wegovy) or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (e.g., Zepbound).
- iv.** The medication will be used concomitantly with behavioral modification and a reduced-calorie diet; AND
- v.** Patient meets one of the following (a or b):

- a) Patient is able to tolerate a Zepbound maintenance dose of 5 mg, 10 mg, or 15 mg once weekly: Approve for 1 year; OR
- b) Approve for up to 4 months if the patient meets both of the following [(1) and (2)]:  
Note: Approve a sufficient duration for 12 consecutive months of therapy (for example, if the patient has completed 8 months of Zepbound therapy, approve for 4 additional months).
  - (1) Patient has received < 12 consecutive months of Zepbound; AND
  - (2) According to the prescriber, the patient is continuing to titrate the Zepbound dose to a target of 10 mg once weekly or 15 mg once weekly.  
Note: Although 5 mg once weekly is an acceptable maintenance dose, the patient should be able to achieve the 5 mg once weekly maintenance dose within the 8 months of initial therapy provided above.

#### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Saxenda, Wegovy, and Zepbound is not recommended in the following situations:

1. **Concomitant Use with Other Weight Loss Medications.** Concomitant use with other medications intended for weight loss is not recommended.<sup>2,9,11</sup> Note: Examples of other medications FDA-approved for weight loss include but are not limited to phentermine (Lomaira, generic), benzphetamine, diethylpropion, phendimetrazine, Contrave (naltrexone/bupropion extended-release tablets), Qsymia (phentermine/topiramate extended-release capsules), and Xenical (orlistat 120 mg capsules). Additionally, Alli (orlistat 60 mg capsules) is available over-the-counter.
2. **Concomitant Use with other Glucagon-Like Peptide-1 (GLP-1) Agonists or GLP-1/ Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists.** Saxenda, Wegovy, and Zepbound should not be combined with each other or with any other GLP-1 agonists.<sup>1,2,9</sup> Other GLP-1 and GLP-1/GIP products are FDA-approved for type 2 diabetes and are not indicated for chronic weight management. Note: Examples of other GLP-1 agonists include but are not limited to Adlyxin (lixisenatide subcutaneous [SC] injection), Byetta (exenatide SC injection), Bydureon (exenatide extended-release SC injectable suspension), Bydureon BCise (exenatide extended-release SC injectable suspension), Ozempic (semaglutide SC injection), Rybelsus (semaglutide tablets), Trulicity (dulaglutide SC injection), and Victoza (liraglutide SC injection). An example of a GLP-1/GIP agonist is Mounjaro (tirzepatide SC injection).
3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.



## REFERENCES

1. Wegovy® subcutaneous injection [prescribing information]. Plainsboro, NJ: Novo Nordisk; March 2024.
2. Saxenda® subcutaneous injection [prescribing information]. Plainsboro, NJ: Novo Nordisk; April 2023.
3. Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015;100(2):342-62.
4. Garvey WT, Mechanick JL, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Cardiology comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract*. 2016;22 Suppl 3:1-203.
5. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017;102(3):709-757.
6. Grunvald E, Shah R, Hernaez R, et al; AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity. *Gastroenterology*. 2022;163(5):1198-1225.
7. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. *Pediatrics*. 2023;151(2):e2022060640.
8. American Diabetes Association. Standards of medical care in diabetes – 2023. *Diabetes Care*. 2023;46(Suppl 1):S1-S291.
9. Zepbound™ subcutaneous injection [prescribing information]. Indianapolis, IN: Eli Lilly; November 2023.
10. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; for the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389(24):2221-2232
11. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;384(11):989.
12. Weghuber D, Barrett T, Barrientos-Pérez M, et al; STEP TEENS Investigators. Once-weekly semaglutide in adolescents with obesity. *N Engl J Med*. 2022;387(24):2245-2257.